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Background Patients on cardiopulmonary bypass (CPB)
have an increased susceptibility to postoperative bleeding.
Previous reports using desmopressin acetate (DDAVP) for
the prevention of postoperative bleeding have given contra-
dictory results, whereas the protease inhibitor aprotinin has
been shown to reduce blood loss after this type of surgery.
This randomized study was performed to assess the efficacy
of DDAVP versus aprotinin in the prevention of bleeding
after CPB.
Methods and Results One hundred nine of 122 eligible
patients were randomized to four different groups: Group A
(n=28) received aprotinin starting with a bolus of 2x 106 KIU
followed by a continuous infusion of 0.5 x 106 KIU/h until the
end of surgery; group B (n=25) received of DDAVP 0.3 ,g/kg
IV on completion of CPB; group C (n=28) received two doses
of DDAVP, the first as in group B and an additional dose 6
hours after surgery; group D (n=28) received no treatment.
There was a marked reduction of postoperative blood loss
either at 12 hours (P<.01) or 72 hours (P<.02) in the aprotinin
group compared with all other groups, whereas no significant
effect was observed in either of the two DDAVP regimens. A
significant reduction in the amount of blood used was ob-
served only in the aprotinin group (P<.01). Of the plasma
fibrinolytic components assayed, there was a significant reduc-
tion of the fibrin degradation product generation in the
aprotinin group (P<.001), whereas a significant systemic hy-
perfibrinolysis was observed in both DDAVP-treated groups
and the control group. No side effects related to the study
drugs were observed in any patient.
Conclusions Aprotinin inhibited fibrinolysis; this correlated
with a significant reduction of postoperative blood loss and
need for blood replacement after CPB. Neither one nor two
doses of DDAVP had a beneficial effect. Aprotinin offers a
better alternative than DDAVP in the prevention of bleeding
after CPB. (Circulation. 1994;90:921-927.)
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D espite the improvement in surgical techniques
and extracorporeal circulation, excessive peri-
operative bleeding continues to complicate
cardiopulmonary bypass (CPB) surgery. Patients under-
going CPB often require blood component therapy,
reoperation for bleeding control is sometimes neces-
sary, and occasionally life-threatening hemorrhage oc-
curs during the postoperative period.1.2
The majority of patients bleed primarily from the
operative site, and the excessive bleeding is related to
the surgical damage to blood vessels. In some patients,
however, diffuse systemic bleeding suggests an acute
acquired hemostatic defect. The basic pathophysiology
of altered hemostasis associated with CPB remains
confusing because of the complexity of the hemostatic
process and the many uncontrolled variables associated
with CPB, such as the surgical procedure, type of
anesthesia, drug administration, transfused blood prod-
ucts, hypothermia, hemodilution, and the type of oxy-
genator. The abnormalities most frequently found in-
clude heparin and protamin excess, heparin rebound,
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low platelet count, low fibrinogen and other coagulation
factors, primary fibrinolysis, and disseminated intravas-
cular coagulation.3-7 However, the major contributor to
abnormal hemostasis seems to be the alteration of
platelet function resulting from a reversible membrane
abnormality.8,9
Research during the past decade has been addressed
at reducing postoperative blood loss and transfusion
requirements in routine CPB operations. Among the
different treatment schedules used, desmopressin ace-
tate (DDAVP) and fibrinolysis inhibitors seem to be the
most efficacious in diminishing blood loss after cardiac
surgery.
DDAVP is a synthetic analogue of the neurohypophy-
seal nonapeptide arginine vasopressin. It is known that
this hormone causes the appearance of larger von
Willebrand factor (vWF) multimers in addition to in-
creased concentrations of vWF and factor VIII; thus, a
role for DDAVP has been indicated in patients with
mild hemophilia or von Willebrand's disease.'0 DDAVP
has also been shown to shorten the bleeding time in
other conditions, including uremia, chronic liver dis-
ease, and aspirin ingestion.11-'3 Finally, although
DDAVP has been shown to be effective in reducing
bleeding after orthopedic14 and cardiac surgery,"5 the
beneficial effect in CPB remains unclear.16,17
Aprotinin is a serine protease inhibitor with inhibi-
tory effects on human plasmin, trypsin, and kallikrein
that has been shown to reduce postoperative blood loss
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and the need for blood transfusion in cardiac surgery
through an inhibition of fibrinolysis mechanisms.18,19 As
already mentioned, alterations in platelet surface mem-
brane receptors have been described during extracorpo-
real circulation,920 and it appears that aprotinin also
preserves platelet function.19
Previous studies have reported some adverse effects
attributable to the use of both DDAVP and aprotinin,
especially in patients undergoing revascularization pro-
cedures, since they may increase the risk of graft
thrombosis.2122
We therefore undertook a randomized clinical study
to compare the effectiveness of aprotinin versus
DDAVP in reducing postoperative blood loss in pa-




To be eligible for recruitment, patients had to satisfy the
following inclusion criteria: age >18 years and valvular or
coronary disease. Patients were excluded for the following
reasons: emergency surgery, known hemostatic defect, hepatic
and renal insufficiency, previous exposure to the study drugs,
and use of other techniques of blood saving. Patients receiving
nonsteroidal anti-inflammatory drugs or aspirin before surgery
were not excluded, because a large percentage of patients
undergoing routine CPB at our institution are on these med-
ications up to the time of surgery.
Heparin was administered at an initial dose of 300 U/kg to
maintain the activated clotting time >400 seconds (Hemo-
chrom Internationaltechnique). CPB was instituted with a
two-stage right atrial and ascending aortic cannula. A roller
pump maintained nonpulsatile flow between 2.0 and 2.4
L. minm' m`2. Moderate systemic hypothermia (25°C) was
maintained during aortic occlusion. After discontinuation of
CPB, heparin was reversed with protamine sulfate (1.5:1) by
slow intravenous infusion.
Study Design
The protocol was approved by our hospital's Clinical Assays
Committee. After informed consent was obtained, a prospec-
tive randomized trial involving 122 patients was begun. Of the
total number of patients admitted to the study, 13 (4 in the
placebo group and 9 in the treatment groups) were excluded
from subsequent analysis because they did not complete the
study. The remaining 109 patients were assigned to one of the
following groups.
Group A patients (n=28) received aprotinin (Trasylol)
supplied by Bayer in bottles containing 70 mg aprotinin
(500 000 kallikrein inactivator units, KIU) in 50 mL 0.9%
saline solution without further additives or preservative sub-
stances. Patients in this group received a bolus infusion of
2X 106 KIU within 30 minutes after induction of anesthesia
followed by a continuous infusion of 0.5 x 106 KIU/h until the
patient left the operating room and an additional bolus of
2X 106 KIU aprotinin in the pump prime by replacement of
crystalloid solution.
Group B patients (n=25) received DDAVP, 0.3 jig/kg body
wt (supplied by Ferring Pharmaceuticals) in a 50-mL saline
solution over a period of 20 minutes, given intravenously on
completion of CPB and immediately after administration of
protamine.
Group C patients (n=28) received two doses of DDAVP,
0.3 jig/mL, the first as in group B and an additional dose 6
hours after surgery.
Group D patients (n-28) did not receive aprotinin or
DDAVP and were considered a control group.
Blood Sampling
Blood samples were obtained before operation, at the end of
bypass, and 90 minutes and 24 hours after surgery. Venous
blood was drawn in Vacutainer tubes (Becton Dickinson)
containing 0.129 mol/L sodium citrate in a 9:1 proportion.
Platelet-poor plasma was prepared by centrifugation at 1500g
for 20 minutes and snap-frozen in aliquots at -70°C until used.
For measurements of hemoglobin and hematocrit, blood was
mixed with EDTA.
Procedures
Hematocrit and hemoglobin were determined by routine
analysis with a Coulter S Plus II. Plasminogen and a2-antiplas-
min were determined by amidolytic assays (Coatest Plasmino-
gen and Coatest Antiplasmin, Kabi Diagnostica). Plasminogen
activator inhibitor type 1 (PAI-1) activity was measured with
chromogenic substrates as previously described.23 Tissue-type
plasminogen activator (TPA) antigen was measured with a
commercially available ELISA assay (TintElize t-PA,
Biopool). Fibrin degradation products (FbDP) were assayed
by use of a specific monoclonal antibody as described by
Nieuwenhuizen24 (Fibrinostika FbDP, Organon Teknika).
Data presented in the figures and used in the statistical
calculations are values measured on plasma samples corrected
for hemodilution, as assessed by the difference between each
hematocrit with respect to its own baseline value.
The postoperative blood loss in the first 72 hours was
determined by measuring the drainage losses. Red cell trans-
fusions within the first 72 hours were also measured. Blood
pressure and urine output in the first 24 hours were recorded.
Investigators and laboratory personnel were blinded to
treatment or control groups.
Statistical Analysis
Results are expressed as mean±SD. Student's t test was
used to compare mean values, and Student's t test for paired
observations was used to compare the mean values of the same
variable at different times. Statistical analysis for group com-
parisons was performed with a two-way ANOVA. Differences
were considered to be significant when P<.05.
Results
One hundred twenty-two patients who consented to
participate in this trial were randomized into four
different groups, and 109 completed the study. The
baseline characteristics, the main diagnoses, and types
of surgery are listed in Table 1. There were no signifi-
cant differences with regard to any of the characteristics
analyzed among the four group of patients. Only one
patient in the control group had a previous intrathoracic
operation, compared with the greater number of pa-
tients in the treated groups. However, no significant
differences could be demonstrated.
All patients had normal coagulation parameters,
platelet counts, and hemoglobin levels before surgery.
Blood Loss and Transfusion Requirements
As shown in Table 2 and Fig 1, there was a marked
reduction (P<.01) of postoperative blood loss during the
first 12 hours in the group treated with aprotinin
(137.9+70.6 mL/m2) compared with groups B (278.7+
164.1 mL/m2), C (208.8+111.7 mL/m2), and D (214.5+
120.8 mL/m2), with no differences between groups B and C
and the control group. The total postoperative blood loss
at 72 hours was also reduced (P<.02) in the aprotinin
group (358.5+156.3 mL/m2) compared with groups B
(551.8+324.1 mL/m2), C (498.5+235.6 mL/m2), and D
(438.7+228.1 mL/m2).
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TABLE 1. Characteristics of the Patients Studied
Group A Group B Group C Group D
(n=28) (n=25) (n=28) (n=28)
Age, y 58.9±10.0 56.6+8.8 57.3±76 56.3±10.1
Sex, M/F 16/12 14/11 20/8 22/6
Body surface, m2 1.7±0.2 1.7±0.1 1.8±0.2 1.8+0.1
Type of surgery
Coronary 13 12 16 14
Valvular 14 12 11 14
Mixed 1 1 1 0
Reintervention 4 4 6 1
Duration of extracorporeal circulation, min 127.3±45.4 122.4±34.4 131.6±39.3 121.3±36.2
Values are mean±SD.
There was also a significant reduction in the amounts of
bank blood used in the aprotinin group, either in the first
12 hours (P<.02) or at 72 hours after surgery (P<.01)
(Table 2). The total blood transfused was 366.1+331.9
mnIm2 in group A, which was significantly less than in
groups B (740.4+416.3 mbrm2), C (662.8+380.7 mUm2),
and D (678.1±462.2 mbUm2), without differences in the
two DDAVP-treated groups compared with the control
group.
Hemoglobin Levels
The preoperative hemoglobin levels were similar in
all groups. At 24 hours after surgery, the levels in all
groups fell a similar amount (Fig 2).
Fibrinolytic System
Table 3 shows the preoperative, intraoperative, and
postoperative evolution of the different fibrinolysis pa-
rameters analyzed in the control group. In patients who
did not receive any treatment, we observed a significant
decrease of plasminogen and a2-antiplasmin (P<.001)
and a marked increase of TPA antigen, PAI-1, and
FbDP (P<.001) intraoperatively compared with the
baseline value. Whereas plasminogen and a2-antiplas-
min showed a tendency to recover in the sample taken
90 minutes after operation with normalization on post-
operative day 1, the TPA, PAI-1, and FbDP concentra-
tions remained significantly elevated after surgery
(P<.01).
There were no significant differences among the three
treatment groups with regard to plasminogen and PAI-1
concentrations in relation to values observed in the
control group (data not shown). TPA antigen (Fig 2)
was slightly elevated in both DDAVP-treated groups
only in the sample taken 90 minutes after surgery, with
differences in relation to the corresponding levels in
groups A or D (P<.05). Whereas the intraoperative and
postoperative levels of a2-antiplasmin did not change
significantly in the aprotinin group with respect to the
preoperative value, a reduction similar to that in the
control group was observed in both DDAVP-treated
groups. a2-Antiplasmin levels recovered in all groups in
the sample taken 24 hours after surgery (Fig 2). A
significant reduction of FbDP generation could be dem-
onstrated in patients receiving aprotinin in the samples
obtained at the end of bypass and immediately after
surgery (P<.001), but no differences in this parameter
were observed in both DDAVP-treated groups in rela-
tion to the control group (Fig 2).
No correlations between the different fibrinolysis
parameters analyzed and either the blood loss or trans-
fusion requirements could be demonstrated.
Side Effects
Neither DDAVP nor aprotinin provoked complica-
tions with regard to blood pressure or urinary output.
No thrombosis, deaths, or severe complications oc-
curred intraoperatively or during the first 10 postoper-
ative days in any patients included in the study.
Discussion
The use of CPB for cardiac surgery is performed
routinely in western countries and is generally regarded
as safe, although these patients are at considerable risk
of postoperative bleeding requiring blood transfusion
and reoperation in approximately 3% of cases. It is well
known that cardiac surgery with CPB results in large
alterations in hemostasis and platelet function, so there
TABLE 2. Results of the Study
Group A Group B Group C Group D
Blood loss, mL/m2
0-12 h 137.9±70.6* 278.7±164.1 208.8±111.7 214.5±120.8
Total, 0-72 h 358.5±156.3t 551.8±324.1 498.5±235.6 438.7±228.1
Red cell transfusions, mL/m2
0-12 h 164.5±197.5t 366.9±233.6 238.1±258.6 340.9+324.3
Total, 0-72 h 366.1 ±331.9* 740.4±416.3 662.8±380.7 678.1±462.2
*P<.01 and tP<.02 aprotinin in relation to all other groups.
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FIG 1. Scatterplots showing individual distribution of blood loss
(top) and red cell transfusions (bottom) in the treated groups and
in the control group. DDAVP indicates desmopressin acetate.
has been great interest in improving postoperative he-
mostasis by use of drugs that prevent alterations in
those systems.2
This randomized study convincingly shows that apro-
tinin is a useful drug in reducing postoperative blood
loss as well as the need for blood transfusion in patients
undergoing CPB surgery, whereas neither one nor two
doses of DDAVP were able to significantly reduce
either blood loss or transfusion requirements.
The hemostatic properties of DDAVP in patients
undergoing open-heart surgery with CPB were first
studied by Czer et a125 in a prospective nonrandomized
clinical study. Patients treated with DDAVP required
significantly less transfusion of blood products. More-
over, DDAVP infusion shortened the bleeding time and
significantly increased factor VIII and vWF levels. Salz-
man et al'5 performed a double-blind prospective trial
in which patients were randomized to DDAVP or
placebo. The DDAVP-treated patients showed a signif-
icant reduction in intraoperative and postoperative
blood loss and lower red cell transfusion requirements.
In these patients, higher vWF:Ag levels than those in
the placebo group were observed 90 minutes after
infusion. In the light of these results, it seemed that the
beneficial effect of DDAVP in CPB was probably re-
lated to an elevation of vWF in plasma. In another
study, however, the effectiveness of DDAVP in reduc-
ing blood loss could not be related to the increase of
large vWF multimers.26
In a randomized trial comparing DDAVP versus
placebo, we could not confirm that DDAVP reduces the
total blood loss and transfusion requirements, although
it was observed to significantly reduce intraoperative
blood loss.16 These results were later confirmed by
Hackmann et al.27 Furthermore, four additional studies
did not find significant improvement in postoperative
blood loss,28-31 and one report shows that the total
postoperative blood loss and the red cell transfusion
rates were significantly higher in the DDAVP group
than in the control group, which could be related to the
DDAVP-induced TPA release from endothelial cells
and subsequent fibrinolysis.32
Since, as suggested by our findings, the administration
ofDDAVP was effective only in reducing intraoperative
bleeding, we decided to administer a second dose 6
hours after surgery to establish whether it could also
improve the postoperative blood loss. The results of the
present study clearly indicate that a second dose of
DDAVP given after surgery does not reduce postoper-
ative bleeding. It could be speculated that a tachyphy-
laxis phenomenon could hamper the possible benefit of
DDAVP, but it is unlikely that later administration
could be more effective.33 There is evidence that the
administration of DDAVP may be useful in reducing
hemorrhage in patients at high risk, such as those
undergoing valve replacement combined with coronary
artery bypass graft surgery or in those with aspirin-
related bleeding after bypass, or even in patients with
severe platelet dysfunction and excessive mediastinal
bleeding after termination of CPB.3435 However, the
majority of patients who undergo cardiac surgery with-
out complications will have only moderate blood loss,
and in these cases DDAVP does not appear to offer any
advantages beyond those of conventional techniques to
reduce the use of blood products. Thus, DDAVP could
be administered to patients who are at particular risk of
bleeding but not routinely to all patients undergoing
CPB surgery.17'36
Aprotinin has been used in patients having cardiac
surgery since the 1960s on the basis of a reduction of the
hyperfibrinolytic state observed during open-heart op-
erations.37,38 These reports indicated that relatively low
doses of aprotinin significantly reduced fibrinolytic ac-
tivity but had no effect on postoperative bleeding. More
recent data suggested that high-dose aprotinin might
reduce bleeding after cardiac surgery not only by inhib-
iting fibrinolysis but also by preserving platelet func-
tion.18'19,39-42 These results have clearly been confirmed
in the present study, in which a high-dose aprotinin
regimen significantly diminished the blood loss and
transfusion requirements compared with either the con-
trol group or the two DDAVP-treated groups.
Although it has been suggested that both DDAVP
and antifibrinolytic drugs may cause premature saphe-
nous vein graft occlusion, several prospective studies
reported no increase in the frequency of occlusion.27,39'43
Two recent reviews evaluating the incidence of throm-
botic events in controlled trials of DDAVP in cardiac
surgery also indicate that DDAVP does not increase the
incidence of thrombosis.44'45 In our study, there were no
incidences of suspected acute graft thrombosis in either
of the treated groups, although no patients in either
group underwent angiography to demonstrate patent
bypass grafts. Very recently, however, Cosgrove et a146
reported a significant incidence of graft thrombi in
postmortem examinations of patients receiving aproti-
nin who died during the study. The evidence of vein
graft thrombosis raises the question of a hypercoagula-
ble state that may adversely influence patient outcome.
Other complications with the use of aprotinin include
allergic reactions, renal toxicity, and heparin resis-
tance.47 We observed no significant allergic complica-
%}
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FIG 2. Graphs showing mean hemoglo-
bin, tissue-type plasminogen activator (t-
PA), a2-antiplasmin, and fibrin degradation
product (FbDP) concentration in blood
samples obtained before operation, at the
end of bypass, and 90 minutes and 24
hours after surgery in aprotinin, one dose
of desmopressin acetate (DDAVP), two
doses of DDAVP, and control groups.
*P<.001 aprotinin compared with all other
groups; **P<.05 aprotinin compared with
one dose DDAVP; #P<.05 both DDAVP-
treated groups compared with aprotinin
and control groups.
Basal End bypass 90 mmn 24 hiurs
tions or drug interactions in our study. In an attempt to
document whether the beneficial effect of aprotinin in
reducing bleeding would be related to an inhibition of
fibrinolysis, we compared the changes observed in dif-
ferent fibrinolysis parameters measured preoperatively,
intraoperatively, and postoperatively in the placebo
group and in the treated groups. Hyperfibrinolysis dur-
ing and after CPB is well documented in the litera-
ture48-50 and was also found in the present study, as
demonstrated by a significant decrease of plasminogen
and a2-antiplasmin and an increase of TPA and FbDP
observed in the control group. Whether this hyperfi-
brinolytic state is a primary event or secondary to the
activation of the coagulation system is not completely
understood,51 but the clinical significance of hyperfi-
brinolysis for the amount of postoperative blood loss is
well shown by laboratory data and the results of thera-
peutic intervention studies.
Neither of the two DDAVP regimens significantly
improved the intraoperative and postoperative fibrino-
lysis alterations observed in the control group, but they
induced a slight increase of TPA concentrations. It has
been shown that DDAVP induces a rapid release of
TPA from its endothelial cell storage sites with a
subsequent fall in PAI-1 activity, which was thought to
be due to the formation of TPA/inhibitor complexes.52
The lack of differences in the DDAVP-treated patients
compared with the control group might be due to the
transient effect of the drug reaching a peak 20 minutes
after intravenous delivery and thus not detected in the
sample obtained at the end of bypass. Aprotinin inhib-
ited excessive fibrinolysis by preventing the plasminogen
and a2-antiplasmin consumption and FbDP generation.
Whereas the observed changes in a2-antiplasmin might
be an artifact in relation to the chromogenic assay, it
seems clear that aprotinin treatment resulted in a
reduction of intraoperative and postoperative hyperfi-
brinolysis as assessed by the decrease of FbDP levels.
Other studies have used a similar schedule to maintain
a constant intraoperative plasma aprotinin concentration
of approximately 4 ,umol/L. This concentration has been
reported to inhibit plasmin in vitro, to prevent platelet
activation and aggregation, and to block the loss of platelet
membrane glycoprotein Ib during CPB.4lA2,3,4 It has
TABLE 3. Values of Fibrinolysis Parameters Studied In the Control Group
End of
Preoperative Bypass 90 min 24 h
Plasminogen, % 91.7±15.5 78.2±20.4* 82.5±23.5t 92.6±27.8
a2-antiplasmin, % 92.2±12.4 55.1±21.4* 67.5±20.7* 81.3±19.3t
TPA antigen, ng/mL 7.9±5.5 22.1±10.9* 23.0±6.7* 15.4±9.1t
PAI-1, U/mL 9.6±8.4 24.3±21.7t 34.4±16.9* 26.8+17.3t
FbDP, 1£g/mL 0.3±0.2 3.7±2.5* 3.1 ±1.9* 0.9+0.7t
TPA indicates tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor; and FbDP, fibrin
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been hypothesized that aprotinin reduces blood loss after
CPB by stabilizing the platelet membrane by means of its
antifibrinolytic effects. However, it is not clear whether
these effects of aprotinin on normalizing hemostatic func-
tion might be exclusively related to inhibition of plasmin or
inhibition of other coagulation cascade serine proteases.5
Other lysine-analogue antifibrinolytic preparations
such as E-aminocaproic acid and tranexamic acid also
appear safe in decreasing blood loss and transfusion
requirements after cardiac surgery.56'57 Interestingly,
Horrow et al58 investigated the separate and combined
hemostatic effects of tranexamic acid and DDAVP
during cardiac surgery. DDAVP exerted no hemostatic
effect with or without prior administration of antifibri-
nolytic drug.
In summary, aprotinin inhibited fibrinolysis, and that
correlated with a significant reduction of postoperative
blood loss and need for blood replacement after CPB.
Although DDAVP may be effective in reducing hemor-
rhage in patients at high risk, our results clearly indicate
that in the majority of patients, the protease inhibitor
aprotinin offers a better alternative than DDAVP in the
prevention of bleeding after cardiopulmonary bypass
surgery.
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